China's innovative pharmaceutical company, HENGRUI PHARMA (01276.HK) will raise $9.89 billion in its IPO at a cap offer price of $44.05, IFR quoted sources as saying.
It was previously rumored that, due to strong demand for IPO subscription, HENGRUI PHARMA would close institutional investor subscriptions a day early at 5 PM on Monday (19th). It is reported that institutional investor demand has topped the entire offering size.
(HK stocks quote is delayed for at least 15 mins.)
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。